Precision BioSciences, Inc.
NEWS
Precision BioSciences recently received a notice of allowance for a new patent for PBCAR19B, its stealth cell, CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma.
Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement.
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
It was a moderately busy week for clinical trial news. Here’s a look.
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Research Triangle Park Facility to Manufacture Precision’s Pipeline of Off-the-Shelf CAR T Product Candidates to Support Clinical Trials
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regions. Take a look.
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
JOBS
IN THE PRESS